▎Armstrong2026年2月5日,复宏汉霖发布公告,宣布将PD-1抗体斯鲁利单抗的日本权益授权给卫材。根据协议,卫材支付7500万美元预付款,8001万美元监管里程碑,2.3333亿美元销售额里程碑,以及两位数百分比的销售分成,交易总金额高达3.88亿美元。斯鲁利单抗已经获批肺癌、食管鳞癌适应症,还有多个适应症在临床开发过程中。2026年,斯鲁利单抗将迎来多个里程碑,包括国内胃癌围手术期加速...
Source Link▎Armstrong2026年2月5日,复宏汉霖发布公告,宣布将PD-1抗体斯鲁利单抗的日本权益授权给卫材。根据协议,卫材支付7500万美元预付款,8001万美元监管里程碑,2.3333亿美元销售额里程碑,以及两位数百分比的销售分成,交易总金额高达3.88亿美元。斯鲁利单抗已经获批肺癌、食管鳞癌适应症,还有多个适应症在临床开发过程中。2026年,斯鲁利单抗将迎来多个里程碑,包括国内胃癌围手术期加速...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.